| Objective: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by overactivation of self-reactive T and B cells, production pathogenic autoantibody and immune complexes。Lupus nephritis (LN) is one of the most frequent and serious complications that occurs in this nonorgan-specific disease.B lymphocytes have a high degree of activation of a large number of auto-antibodies leading to a variety of tissues and organs involved are the main pathological mechanism of SLE. On the generation of autoantibodies and disease of B lymphocytes to study the relationship between the occurrence and development of great significance. CD38 + is a B -cell activation and differentiation of one of the hallmarks of, cd19 + is a B cell surface antigen specific molecules, cells can regulate the function of activation and proliferation.The Toll-like receptors (TLRs) are pattern recognition receptors (PRRs), which can recognize : many pathogen-associated molecule patterns (PAMPs)。TLRs play an important role between innate immune system and adaptive immune system。To study the state of B lymphocytes activation and mRNA expression of toll like receptor 7 on peripheral blood nuclear cells ( PBMCs) in patients with SLE。The correlations between TLR7 and clinical parameters were also analyzed , in order to investigate the mechanism and clinical significance of TLR7 in patients with SLE。Methods: We chose 30 SLE patients and 15 healthy controls. The percentages of CD19+B lymphocytes and CD38+B lymphocytes and CD19+CD38+B lymphocytes in PBMCs were detected by flow cytometry and mRNA expression level of TLR7 was measured with semi - quantitative reverse transcription- polymerase chain reaction (RT- PCR) of patients with SLE。The relationship of the expression level of TLR7 and SLEDAI scores was analyzed。Then according to SLEDAI score,we divided 30 SLE patients into 2 groups: active group (16 individuals); non-active group(14 individuals)。Results:1,SLE patients with active B cells in peripheral blood CD19 +, CD38 +, CD19 + CD38 + expression rate(%) (7.25±1.8; 68.3±10.5;8.1±1.1)higher than in patients with SLE in remission(%) (5.7±1.9; 48±9.3; 5.9±2.1) and normal control group(%) (3.42±1.25; 32.3±12.1;4.8±1.2) ,the difference was statistically significant (P <0.01). Patients with active B lymphocyte or plasma cell precursor cells, the existence of clonal dysplasia. CD19 + and the relationship between activity index:the difference was statistically significant,r = 0.786, P <0.01; CD38 + and the relationship between activity index: the difference was statistically significant ,r = 0.89, P <0.01;CD19 + CD38 + and the relationship between activity index: the difference was statistically significant ,r = 0.804, P <0.01; Patients with active B lymphocyte or plasma cell precursor cells, the existence of clonal dysplasia. CD19 + and the relationship between ANA:the difference was statistically significant,r = 0.859, P <0.01; CD38 + and the relationship between ANA: the difference was statistically significant ,r = 0.946, P <0.01;CD19 + CD38 + and the relationship between ANA: the difference was statistically significant ,r = 0.862, P <0.01.Description SLE peripheral blood B cells of patients with CD19 +, CD38 +, CD19 + CD38 + expression and the SLEDAI score and ANA was positively correlated.2,Peripheral blood of patients with active SLE express TLR7mRNA of (1.45±0.35) was significantly higher than that in patients with SLE in remission group TLR7mRNA expression in peripheral blood (0.75±0.25), the difference was statistically significant (P <0.01), and normal control group TLR7mRNA expression in peripheral blood (0.6±0.15), the difference was statistically significant (P <0.01); remission and normal control group, there was no significant difference (P> 0.05).TLR7mRNA peripheral blood of patients with SLE the expression level and SLEDAI score was a positive correlation between the difference was significant, r = 0.92, P <0.01.Conclusion: In patients with systemic lupus erythematosus B lymphocytes CD19 +, CD38 +, CD19 + CD38 + abnormal activation。CD19 +, CD38 +, CD19 + CD38 + abnormal activation is the direct cause of disease activity and is abnormal in patients with SLE can not be completely cured with one of the reasons for repeated condition.Peripheral blood of patients with active SLE the expression level of the TLR7mRNA increased, and the expression level was positively correlated with SLEDAI, suggesting that TLR7 might be involved in the process of the occurrence and development of SLE。Therefore peripheral blood CD19 +,CD38 +, CD19 + CD38 + and TLR7 expression levels in patients with SLE may be a direct reflection of the progress of the disease, SLE research for new ideas, but also for clinical diagnosis and treatment based on the provision of laboratory.
|
PDF Full Text Request